PEDIATRICS Vol. 122 No. 2 August 2008, pp. 445-449 (doi:10.1542/peds.2008-1485)
POLICY STATEMENT |
Maternal Phenylketonuria
Elevated maternal phenylalanine concentrations during pregnancy are teratogenic and may result in growth retardation, microcephaly, significant developmental delays, and birth defects in the offspring of women with poorly controlled phenylketonuria during pregnancy. Women of childbearing age with all forms of phenylketonuria, including mild variants such as mild hyperphenylalaninemia, should receive counseling concerning their risks for adverse fetal effects, optimally before conceiving. The best outcomes occur when strict control of maternal phenylalanine concentration is achieved before conception and continued throughout pregnancy. Included are brief descriptions of novel treatments for phenylketonuria.
Key Words: phenylketonuria maternal phenylketonuria pregnancy birth defect prevention
Abbreviations: PKU—phenylketonuria Phe—phenylalanine PAH—phenylalanine hydroxylase BH4—tetrahydrobiopterin PAL—phenylalanine ammonia lyase
The following policy statement has been revised:
- Maternal Phenylketonuria
Pediatrics 107: 427-428.[Full Text]
This article has been cited by other articles:
![]() |
R. Koch Maternal Phenylketonuria and Tetrahydrobiopterin Pediatrics, December 1, 2008; 122(6): 1367 - 1368. [Full Text] [PDF] |
||||





